Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: In a study in the British Journal of Psychiatry, researchers analyzed comedians from Australia, Britain and the United States and found they scored significantly higher on four types of psychotic characteristics compared to a control group of people who had non-creative jobs. The traits included a tendency towards impulsive or anti-social behavior, and a tendency to avoid intimacy. “The creative elements needed to produce humor are strikingly similar to those characterizing the cognitive style of people with psychosis - both schizophrenia and bipolar disorder,” said Gordon Claridge of the University of Oxford’s department of experimental psychology, who led the study. Although the traits in question are known as “psychotic”, Claridge said, they can also represent healthy equivalents of features such as moodiness, social introversion and the tendency to lateral thinking. “Although schizophrenic psychosis itself can be detrimental to humor, in its lesser form it can increase people’s ability to associate odd or unusual things or to think ‘outside the box’,” he said. “Equally, manic thinking - which is common in people with bipolar disorder - may help people combine ideas to form new, original and humorous connections.”  The researchers recruited 523 comedians - 404 men and 119 women - and asked them to complete an online questionnaire designed to measure psychotic traits in healthy people. The traits scored were “unusual experiences”, such as belief in telepathy and paranormal events, “cognitive disorganization” such as difficulty in focusing thoughts, “introvertive anhedonia” - reduced ability to feel social and physical pleasure, and “impulsive non-conformity”, or tendency towards impulsive, antisocial behavior. The same questionnaire was also completed by 364 actors - who are also used to performing in front of an audience - as a control group, and the comedians’ and actors’ results were compared to each other as well as a general group of 831 people who had non-creative jobs. The researchers found that comedians scored significantly higher on all four types of psychotic personality traits compared to the general group. Most striking were their high scores for impulsive non-conformity and introverted personality traits, the researchers said. The actors scored higher than the general group on three types - but did not display high levels of introverted personality traits.
Example Output: Comedians have psychotic personality traits, study finds.

Example Input: His bout with depression reached its nadir in 2014 after a second DUI arrest. That’s when the most decorated Olympian of all time checked himself into a rehabilitative center in a desperate effort to make sense of it all. “When I was in my room and not wanting to talk to anybody for a number of days and not wanting to be alive, I wanted to see what other roads I could take to see if there was help,” Phelps recalled. The treatment he received — and continues to receive — charted his post-Olympic course. “I know it’s something that changed my life and saved my life and allowed me to be able to be where I am today, enjoying the platform of talking about something that’s so important,” Phelps told The Associated Press in an interview Tuesday. Because he is willing to share his story of depression and raise awareness of mental health issues, Phelps was given the fifth annual Morton E. Ruderman Award in Inclusion on Tuesday night in Boston. After participating in four Olympic Games and collecting 28 medals, including 23 gold, Phelps has dedicated his time and energy to promoting the importance of water safety and advocating for the de-stigmatization of mental health problems through the Michael Phelps Foundation. “When I first really opened up about the struggles that I had in ’15, obviously I dreamed of being able to get more publicity to this and to really share my journey and have other people share their journeys with me as well,” Phelps said. “Honestly, I never thought it would be as big as this, but it’s been a true dream to be able to watch the growth that mental health has taken, almost being at center stage.” To say this endeavor has been fulfilling is an understatement. “Through this, if I can save one life, two lives, five lives, a thousand, a million, to me that’s so much more important than winning a gold medal,” he said. The 33-year-old Phelps believes his bout with depression is a story that many can share, including CEOs and other retired athletes. After accomplishing every goal he set for himself, what was left to do? “Probably my first real depression spell was after 2004, then the next big one was after 2008,” he said. “When you set out to be an Olympian, your whole life is put on hold. All the eggs are in one basket. I would say 2004, 2008, 2012, partly after ’16 (all Olympic years) I’ve dealt with pretty severe depression spells. I was kind of lost at that point.” The Baltimore native is in a far better frame of mind now. “To have my wife (Nicole Johnson), who’s always by my side, two amazing little boys at home and a third one on the way, I’m extremely thankful of the support I’ve had to get me through these times,” Phelps said. The Ruderman Award is given to individuals who are passionate about providing opportunities for others. Phelps certainly fits that description. “Michael Phelps is a unique leader who has used his fame and status as the greatest swimmer of all time to challenge our society to remove stigma surrounding mental health,” said Jay Ruderman, president of the Ruderman Family Foundation. “For me, this award means everything because this is where my passion is and the next chapter of my life is really heading,” Phelps said. “We’re kind of scratching the surface of what can be done, and I’m looking forward to continuing this journey and accomplishing some of the goals that I have — de-stigmatizing mental health and just getting the point across that it’s OK to not be OK.” ___ More AP sports: https://apnews.com/apf-Sports and https://twitter.com/AP_Sports
Example Output: Phelps honored for honesty on mental health, helping others.

Example Input: The FDA evaluates drugs without considering costs, which is why they are not discussed in this news release. We hope the FDA will also begin commenting on the projected cost of a drug and its cost-effectiveness. In this case, costs are very steep. An NBC.com story on the approval which we also reviewed, predicts the drug will cost $37,000 annually. It’s unknown if Dupixent will be covered by health insurance. In terms of benefits, the release offers the following: “Overall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.” But readers are left to interpret on their own what “greater response” and “a reduction in itch” mean. The release would have been better if it had told readers how the improvement was measured and how many patients experienced improvement rather than using the term “overall.” The release gets an acceptable rating in this category since it mentions that the drug can cause serious allergic reactions and eye problems including conjunctivitis (pinkeye) and keratitis (inflammation of the cornea). It also cautions that people with asthma shouldn’t use the drug since it hasn’t been tested for safety in these patients. The release should also have noted that regulators don’t know if there are any long-term harms associated with Dupixent use. None of the trials exceeded 16 weeks. The release describes who was studied and for how long, and offers a bare-bones description of the types of studies: “The safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).” The FDA doesn’t provide a link to the studies or their titles and where they were published. The release would be more complete had that information been included. It would help journalists and people with eczema and would be a significant improvement to FDA releases. The release does not engage in disease-mongering. Instead it offers a clear description of what eczema is and what causes the condition. There is no mention of who funded the research leading to the FDA approval, although many readers will assume it was supported by the manufacturer Regeneron. The release gets a borderline satisfactory for mentioning topical corticosteroids as an alternative treatment for eczema but neglects to mention that other pharmaceuticals are also now available for treating it. Whether or not this medication will be covered by insurance is a huge concern. Its high cost will affect how many people can access this new drug. Its availability should have been addressed in the release. It’s newsworthy whenever the FDA approves a new drug. This appears to be the first biologic, injectable treatment for eczema. The release does not use any unjustifiable language.
Example Output:
FDA approves new eczema drug Dupixent